Oncotelic Therapeutics Highlights Advanced Drug Delivery in BioMedWire Editorial

Oncotelic Therapeutics (OTCQB: OTLC) has been featured in a BioMedWire editorial that examines the biotechnology industry's pivot toward advanced drug delivery technologies to supercharge existing cancer therapies. The article highlights how companies are leveraging nanoparticle delivery systems, intravenous reformulations, and precision pharmacokinetic approaches to improve bioavailability, systemic exposure, tolerability, and dosing consistency. Oncotelic is spotlighted for its Sapu003 program and Deciparticle(TM) platform, which are part of a broader trend toward nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company's strategy is to develop platform technologies with potential applications across multiple oncology and rare disease indications, rather than relying on a single therapeutic candidate.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond internal programs, the company licenses and co-develops select drug candidates through strategic partnerships, including a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.

The full press release is available at https://ibn.fm/eoPhj. For continuous updates, investors can visit the company's newsroom at https://ibn.fm/OTLC. The editorial was syndicated by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which delivers press release syndication and corporate communications solutions.